Ambagon Therapeutics is committed to aggressively expanding the boundaries of medicine through treatments that modulate some of the most challenging and potentially impactful targets identified across the proteome, with the goal of treating diseases that currently lack a cure and helping patients live longer and healthier lives. The team is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways. These small molecule stabilizers of 14-3-3:client complexes have the potential to address serious unmet needs in important therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.